What Nucoxia-MR Treats: Main Uses and Benefits

Nucoxia-MR is a combination medication used to help alleviate moderate to severe pain, swelling, and inflammation associated with certain musculoskeletal conditions. The therapy is used in the management of joint discomfort and related symptoms stemming from chronic disorders. Clinical scenarios where this medication is indicated include osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis.

Nucoxia-MR is also specifically indicated to support relief from acute muscle spasms and accompanying pain. By working to ease muscle stiffness and support improved muscle movement, this medication assists in enhancing patient comfort and functional ability. This targeted relief can be particularly helpful in conditions where both inflammation and muscle tightness are contributing to the discomfort.

---

Quick Fact: Relief for Pain and Spasm

Nucoxia-MR is indicated for conditions where inflammation and muscle tightness are contributing to the patient's discomfort, aiming to support improved movement and comfort.

Eligibility for Nucoxia-MR (Etoricoxib and Thiocolchicoside)

Official regulatory information strictly defines the populations who are eligible for or excluded from using Nucoxia-MR, a combination drug.

Population Status	Eligibility Classification (Contraindications and Restrictions)
Populations that Cannot Use	Contraindicated: History of hypersensitivity/allergy to Etoricoxib, Thiocolchicoside, or other NSAIDs (e.g., aspirin).
	Contraindicated: Active peptic ulceration or gastrointestinal (GI) bleeding.
	Contraindicated: Severe hepatic dysfunction (e.g., Child-Pugh score 10) or renal impairment (creatinine clearance < 30 ml/min).
	Contraindicated: Uncontrolled hypertension, Congestive Heart Failure (NYHA II-IV), or established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.
Age and Reproductive Status	Contraindicated: Children and adolescents under 16 years of age.
	Contraindicated: Pregnancy, lactation (breastfeeding), and women of childbearing potential not using effective contraception.
Use Requiring Restriction	Caution/Restriction: Patients with mild to moderate hepatic dysfunction (requires reduced maximum dose) or significant cardiovascular risk factors (e.g., diabetes, smoking, high cholesterol).
	Caution: Elderly persons (over 65 years) and those with pre-existing oedema or a history of GI disease.

This medicine is restricted to adults over the age of 16 years who do not have any of the listed contraindications. Official labeling emphasizes absolute exclusion for severe heart, kidney, or liver conditions, and for reproductive states due to the safety profile of the components.

Interactions with Other Medicines and Products

Nucoxia-MR, containing Etoricoxib and Thiocolchicoside, has officially documented interaction profiles based on regulatory information. These interactions involve effects on drug concentration, renal function, and additive pharmacodynamic activity.

Documented Interactions and Consequences

Interacting Substance/Class	Documented Interaction Statement
Oral Anticoagulants (e.g., Warfarin)	Increased risk of bleeding and hemorrhage, requiring close monitoring of INR levels.
Rifampin	Causes a significant decrease in Etoricoxib plasma exposure (AUC) due to enzyme induction.
Lithium	Etoricoxib reduces Lithium’s renal excretion, leading to an increase in Lithium plasma concentrations.
CNS Depressants & Alcohol	Additive effects increase the risk of sedation, dizziness, and drowsiness (related to Thiocolchicoside).
Antihypertensive Agents	Etoricoxib may reduce the effect of Diuretics, ACE Inhibitors, and ARBs, and potentially impair renal function.

Population and Timing Notes

In patients with moderate hepatic impairment, Etoricoxib exposure is documented to be increased by approximately 40%. Some regulatory guidelines suggest separating the administration of other CNS-active medications from Thiocolchicoside by at least three hours to mitigate additive sedative effects. The concomitant use of Etoricoxib with other NSAIDs or high-dose Aspirin is generally not recommended due to increased risks of gastrointestinal adverse effects.

Nucoxia-MR operates via a dual mechanism involving both peripheral enzyme inhibition and central nervous system (CNS) modulation.

Its primary component acts as a highly selective inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. This molecular interaction suppresses the enzymatic conversion of arachidonic acid into pro-inflammatory prostaglandins, specifically at the site of their biosynthesis. The resultant downstream cascade is a reduced local concentration of these inflammatory mediators, thereby modulating the inflammatory response at the cellular level.

The secondary component is a central-acting agent that primarily modulates polysynaptic reflexes in the central nervous system. It acts at the level of the brainstem and spinal cord by selectively interfering with interneuronal activity. This interaction reduces excessive efferent motor nerve activity without blocking neuromuscular transmission. The combined physiological consequence of COX-2 inhibition and central signal modulation affects both peripheral inflammatory signaling and afferent reflex arcs, modulating overall systemic tone.

The administration of Nucoxia-MR (Etoricoxib and Thiocolchicoside) must strictly follow a healthcare professional's prescription regarding dosage and duration. This medication is for oral use only.

Official Administration Guidelines

• Route and Preparation: Swallow the tablet whole with a glass of water. It must not be chewed, crushed, or broken.
• Dosing Rules: Take the lowest effective dose for the shortest duration necessary, as determined by your doctor. The maximum oral dose of the Thiocolchicoside component (4mg or 8mg tablet strength) must be adhered to.
• Frequency and Timing: Take the tablet once daily, or as directed by the prescribing physician. It can be taken either with or without food. Taking it at a fixed time each day is often recommended for best results.
• Age-Group Use: This medicine is generally intended for use in adolescents and adults aged 16 years and above. It is not recommended for children under 16 years of age.
• Missed Dose: If a dose is missed, take it as soon as you remember. However, if it is almost time for the next scheduled dose, skip the missed dose and continue with the regular schedule. Do not take a double dose to compensate for the forgotten one.
• Procedural Caution: Never stop taking this medicine without consulting your doctor first, even if symptoms improve.

Research Evidence / Overview of Studies for Nucoxia-MR

This section provides an overview of the research and studies that have been conducted on the drug combination Nucoxia-MR, which is a fixed-dose combination of Etoricoxib and Thiocolchicoside. The information here describes what was studied and what remains uncertain, based on the published research landscape.

---

Evidence for Use in Low Back Pain Associated with Muscle Spasms

Clinical research has focused on short-term Randomized Controlled Trials (RCTs) for acute low back pain where muscle spasms are present. These studies monitored outcomes related to physical discomfort and daily functioning or activity level in adult participants, often selecting people experiencing periods of heightened symptoms. The findings describe patterns observed in the studies over short periods, such as 7 to 14 days, helping to contextualize how patients reported their experience during that acute phase.

---

Evidence for Use in Pain Associated with Osteoarthritis and Rheumatoid Arthritis

Specific research on the Nucoxia-MR combination for conditions marked by functional limitations like Osteoarthritis (OA) and Rheumatoid Arthritis (RA) is generally more limited. The evidence related to its use for long-term chronic management is largely derived from research on the Etoricoxib component alone. Findings indicate that the observed outcomes primarily focus on assessing changes in acute symptoms like muscle stiffness. Direct, large-scale combination research on chronic management remains insufficient.

---

Long-Term Studies and Follow-Up Data

Research examined the combination primarily in studies observing responses over defined time intervals that were typically short (days to weeks). Because the follow-up durations were limited, the research provides very little context on what happens after the initial treatment period ends. Long-term effects are not fully established, and data are still emerging concerning the durability of any observed changes.

---

Evidence in Specific Patient Groups (Special Populations)

Studies explored the use of Nucoxia-MR, but the results apply only to the populations studied, which were primarily healthy adults. Data for certain groups remain insufficient. Research is ongoing regarding the use in older adults or those with other existing health conditions. Studies have not widely monitored outcomes in children, pregnant populations, or individuals with severe organ dysfunction.

---

Quality and Consistency of Research Findings

Evidence quality varies across studies, and the overall certainty is affected by limitations in the design and scope of some research. Some studies report how symptoms evolved in the observed populations in a way that suggests a change was observed in some studies. However, the findings were mixed when trying to define the specific contribution of the muscle relaxant component in all contexts.

---

What Is Still Uncertain About Nucoxia-MR

The long-term effects are not fully established, particularly when considering the combination drug over periods exceeding a few weeks. Evidence is limited in defining the specific long-term outcomes and the full range of effects that may be associated with the continuous use of both active ingredients together. Research is needed to more fully explore these areas.

Key Studies & References

1. A Comparative Study of Efficacy and Tolerability of Fixed-Dose Combination of Etoricoxib and Thiocolchicoside versus Thiocolchicoside alone in Patients with Painful Muscle Spasms
2. Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature
3. NEWCOX-TH (Etoricoxib 60 mg & Thiocolchicoside 8 mg Tablets) - Summary of Product Characteristics (SmPC) (Regulatory Document for composition and indications)

Common questions about Nucoxia-MR (FAQ)

---

Q: What is Nucoxia-MR used for?

According to the official product information, Nucoxia-MR is a combination medicine used for the symptomatic relief of pain and spasms associated with acute musculoskeletal conditions. It is specifically indicated for short-term use in adults.

---

Q: What are the active ingredients in Nucoxia-MR?

Regulatory documents state that Nucoxia-MR contains two main active ingredients: Etoricoxib, which belongs to a class of medicines called COX-2 selective inhibitors, and Thiocolchicoside, which is a muscle relaxant.

---

Q: How does Etoricoxib work?

Etoricoxib, one of the components in Nucoxia-MR, works by selectively blocking an enzyme called cyclooxygenase-2 (COX-2). By blocking COX-2, the medicine helps to reduce inflammation and pain.

---

Q: How does Thiocolchicoside work?

Thiocolchicoside, the muscle relaxant in Nucoxia-MR, works on the central nervous system. Its action helps to relieve muscle spasms, which are sudden, involuntary tightenings of the muscles.

---

Q: Can I take Nucoxia-MR with food?

Studies indicate that Nucoxia-MR can be taken with or without food. Taking the tablet with food is often suggested to minimize the possibility of stomach irritation.

---

Q: Is Nucoxia-MR a painkiller only?

No, Nucoxia-MR is considered a combination drug. The Etoricoxib component acts as an anti-inflammatory pain reliever, while the Thiocolchicoside component is a muscle relaxant. This allows the medicine to address both pain and muscle spasms.

---

Q: What is the typical duration of treatment with Nucoxia-MR?

The official product information specifies that Nucoxia-MR is only indicated for short-term use. Treatment is typically limited to a few days, depending on the acute nature of the condition.

---

Q: What should I do if I miss a dose of Nucoxia-MR?

Information regarding a missed dose is detailed in the official 'How to use Nucoxia-MR' section of the product literature. Generally, regulatory documents caution against doubling a dose and advise patients to follow their prescribed schedule.

How to Store and Dispose of Nucoxia-MR?

Storage and disposal must strictly follow official regulatory requirements to maintain product stability and ensure safety.

---

Official Storage Conditions

The tablets must be stored at a temperature not exceeding 30 C. Maintaining this condition is essential for the medicine’s labeled shelf life. Storage requires protection from both light and moisture. The tablets must be kept in the original container or pack in which they were supplied.

Safety and Disposal

It is a mandatory requirement to keep Nucoxia-MR out of the sight and reach of children.

For disposal, unused or expired medicine must be discarded according to local regulations for pharmaceutical waste. The medicine must not be disposed of via household refuse or wastewater to prevent environmental contamination.